A Phase 1 randomized, placebo-controlled, single and multiple-ascending dose study of MYK-224 in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 21 Aug 2019
Price : $35 *
At a glance
- Drugs MYK 224 (Primary)
- Indications Hypertrophic cardiomyopathy
- Focus Adverse reactions
- 21 Aug 2019 Status changed from planning to recruiting, according to a MyoKardia media release.
- 21 Aug 2019 According to a MyoKardia media release, the company anticipates providing topline results from this trial in mid-2020.
- 21 Aug 2019 According to a MyoKardia media release, first patient has been dosed in this study.